[1]刘红云,陈果,曾韫璟,等.脐带间充质细胞对异基因造血干细胞移植术后出血性膀胱炎的疗效及安全性分析[J].第三军医大学学报,2019,41(23):2296-2300.
 LIU Hongyun,CHEN Guo,ZENG Yunjing,et al.Efficiency and safety of umbilical cord mesenchymal stromal cell infusion in treatment of hemorrhagic cystitis after allogenic hematopoietic stem cell transplantation[J].J Third Mil Med Univ,2019,41(23):2296-2300.
点击复制

脐带间充质细胞对异基因造血干细胞移植术后出血性膀胱炎的疗效及安全性分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第23期
页码:
2296-2300
栏目:
专题报道
出版日期:
2019-12-15

文章信息/Info

Title:
Efficiency and safety of umbilical cord mesenchymal stromal cell infusion in treatment of hemorrhagic cystitis after allogenic hematopoietic stem cell transplantation
作者:
刘红云陈果曾韫璟张曦高力
400037 重庆,陆军军医大学(第三军医大学)第二附属医院血液病医学中心,全军血液病中心,创伤、烧伤与复合伤研究国家重点实验室
Author(s):
LIU Hongyun CHEN Guo ZENG Yunjing ZHANG Xi GAO Li

State Key Laboratory of Trauma, Burns and Combined Injury, Medical Center of Hematology, PLA Center for Hematology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China

关键词:
出血性膀胱炎脐带间充质细胞异基因造血干细胞移植CMV病毒BK病毒
Keywords:
hemorrhagic cystitis umbilical cord mesenchymal stromal cells allogeneic hematopoietic stem cell transplantation cytomegalovirus BK virus
分类号:
R329.2; R617.06; R694.3
文献标志码:
A
摘要:

目的探讨输注脐带间充质细胞对异基因造血干细胞移植术后出血性膀胱炎的效果及安全性。方法回顾性分析本中心2014-2018年接受异基因造血干细胞移植后出血性膀胱炎患者的资料,比较输注脐带间充质细胞28例患者(输注组)与未输注脐带间充质细胞24例患者(未输注组)出血性膀胱炎的持续时间、反应率及疼痛评分,观察脐带间充质细胞输注的安全性。结果输注组患者总有效率大于未输注组(100.0% vs 45.8%);输注组患者疼痛消失时间较未输注组明显缩短[(20.6±13.5)d vs (33.9±21.7)d,P<0.05]。与未输注组比较,输注组出血性膀胱炎患者肉眼血尿持续时间明显缩短[(26.3±14.8)d vs (38.9±24.0) d,P<0.05];镜下血尿持续时间也明显缩短[(31.3±13.6)d vs (48.9±22.0)d,P<0.05]。输注脐带间充质细胞不增加血CMV及尿BKV感染率。结论脐带间充质细胞能明显缩短出血性膀胱炎患者的病程,减少痛苦,改善预后,且无毒副作用。

Abstract:

ObjectiveTo investigate the efficiency and safety of the infusion of umbilical cord mesenchymal stromal cells (UCMSCs) for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation (allo-HSCT). MethodsClinical data of patients with hemorrhages cystitis after allo-HSCT in our medical center from January 2014 to December 2018 were collected and analyzed retrospectively in this study. The duration of hemorrhagic cystitis, response rate and pain scores were compared between the patients undergoing UCMSCs infusion (n=28) and those without (n=24). The safety of the infusion was also observed. ResultsThe UCMSCs infusion group had significantly higher overall response rate (100.0% vs 45.8%, P<0.05), shorter median time of pain disappearance (20.6±13.5 vs 33.9±21.7 d, P<0.05), and shorter duration of hematuria macroscopically (26.3±14.8 vs 38.9±24.0 d, P<0.05) and microscopically (31.3±13.6 vs 48.9±22.0 d, P<0.05) when compared the infusion group. Infusion of UCMSCs had no effect on the infection rates of blood cytomegalovirus and urinary BK virus. ConclusionInfusion of UCMSCs can significantly shorten the course of hemorrhagic cystitis, reduce pain, improve general prognosis, and have no side effect in the patients after allo-HSCT.

参考文献/References:

[1]SATYANARAYANA G, HAMMOND S P,BROGE T A Jr,et al. BK polyomavirus reactivation after reduced-intensity double umbilical cord blood cell transplantation[J]. Transpl Immunol, 2015, 32(2): 116-120. DOI:10.1016/j.trim.2014.12.002.
[2]SILVA L D E P, PATAH P A, SALIBA R M, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type[J]. Haematologica, 2010, 95(7): 1183-1190. DOI:10.3324/haematol.2009.016758.
[3]TZANNOU I, PAPADOPOULOU A, NAIK S, et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation[J]. J Clin Oncol, 2017, 35(31): 3547-3557. DOI:10.1200/JCO.2017.73.0655.
[4]曾韫璟, 高力, 陈幸华, 等. 造血干细胞移植后出血性膀胱炎的临床研究[J]. 国际检验医学杂志, 2011, 32(11): 1149-1150, 1153.
ZENG Y J, GAO L, CHEN X H, et al. Study on hemorrhagic cystitis in patients after hematopoietic stem cell transplantation[J]. Int J Lab Med, 2011, 32(11): 1149-1150, 1153.
[5]GAO L, GAO L, GONG Y, et al. Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome[J]. Leuk Res, 2013, 37(11): 1482-1487. DOI:10.1016/j.leukres.2013.08.016.
[6]MANIKANDAN R, KUMAR S, DORAIRAJAN L N. Hemorrhagic cystitis: A challenge to the urologist[J]. Indian J Urol, 2010, 26(2): 159-166. DOI:10.4103/0970-1591.65380.
[7]PARK Y H, LIM J H, YI H G, et al. BK virus-hemorrhagic cystitis following allogeneic stem cell transplantation: Clinical characteristics and utility of leflunomide treatment[J]. Turk J Haematol, 2016, 33(3):223-230. DOI:10.4274/Tjh.2015.0131.
[8]AZZI A. Human polyomavirus BK (BKV) load and haemorrhagic cystitis in bone marrow transplantation patients[J]. J Clin Virol, 1999, 14(2): 79-86. DOI:10.1016/s1386-6532(99)00055-4.
[9]CESARO S, BRUGIOLO A, FARACI M, et al. Incidence and treatment of hemorrhagic cystitis in children given hematopoietic stem cell transplantation: a survey from the Italian association of pediatric hematology oncology-bone marrow transplantation group[J]. Bone Marrow Transplant, 2003, 32(9): 925-931. DOI:10.1038/sj.bmt.1704252.
[10]LEE Y J, ZHENG J T, KOLITSOPOULOS Y, et al. Relationship of BK polyoma virus (BKV) in the urine with hemorrhagic cystitis and renal function in recipients of T cell-depleted peripheral blood and cord blood stem cell transplantations[J]. Biol Blood Marrow Transplant, 2014, 20(8): 1204-1210. DOI:10.1016/j.bbmt.2014.04.017.
[11]DOSIN G, AOUN F, EL RASSY E, et al. Viral-induced hemorrhagic cystitis after allogeneic hematopoietic stem cell transplant[J]. Clin Lymphoma Myeloma Leuk, 2017, 17(7): 438-442. DOI:10.1016/j.clml.2017.05.013.
[12]刘代红, 许兰平, 黄晓军, 等. 异基因造血干细胞移植后迟发性出血性膀胱炎的临床分析[J]. 中华医学杂志, 2007, 87(2): 124-127.
LIU D H, XU L P, HUANG X J, et al. Analysis of etiology of hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation[J]. Natl Med J China, 2007, 87(2): 124-127.
[13]LEE G W, LEE J H, CHOI S J, et al. Hemorrhagic cystitis following allogeneic hematopoietic cell transplantation[J]. J Korean Med Sci, 2003, 18(2): 191-195. DOI:10.3346/jkms.2003.18.2.191.
[14]王彦华, 李春富, 吴学东, 等. 造血干细胞移植后出血性膀胱炎[J]. 实用儿科临床杂志, 2012, 27(3): 218-220.
WANG Y H, LI C F, WU X D, et al. Hemorrhagic cystitis after hematopoietic stem cell transplantation[J]. J Appl Clin Pediatr, 2012, 27(3): 218-220.
[15]FU Y W, WANG Q, ZHOU J, et al. Reduced intensity conditioning and co-transplantation of unrelated peripheral stem cells combined with umbilical cord mesenchymal stem/stroma cells for young patients with refractory severe aplastic Anemia[J]. Int J Hematol, 2013, 98(6): 658-663. DOI:10.1007/s12185-013-1425-6.
[16]BAYGAN A, ARONSSON-KURTTILA W, MORETTI G, et al. Safety and side effects of using placenta-derived decidual stromal cells for graft-versus-host disease and hemorrhagic cystitis[J]. Front Immunol, 2017, 8: 795-804. DOI:10.3389/fimmu.2017.00795.
[17]邱坤银, 廖雄宇, 郭淑仪, 等. 间充质干细胞治疗儿童难治性迟发性出血性膀胱炎疗效和安全性的临床研究[J]. 中国实验血液学杂志, 2018, 26(3): 900-904.
QIU K Y, LIAO X Y, GUO S Y, et al. Efficacy and safety of MSC infusion in treatment of children with refractory LOHC: A clinical study[J]. J Exp Hematol, 2018, 26(3): 900-904.
[18]RINGDEN O, LE BLANC K. Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages[J]. Best Pract Res Clin Haematol, 2011, 24(1): 65-72. DOI:10.1016/j.beha.2011.01.003.

更新日期/Last Update: 2019-12-09